Skip to main content
Erschienen in: Supportive Care in Cancer 3/2017

11.11.2016 | Original Article

Cognitive function and its relationship to other psychosocial factors in lymphoma survivors

verfasst von: Dorothy Krolak, Barbara Collins, Lorelle Weiss, Cheryl Harris, Richard Van der Jagt

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to estimate the prevalence of cognitive disturbance in lymphoma survivors and to explore relationships between cognitive function and other psychosocial factors.

Methods

A package of standardized questionnaires was sent to 622 lymphoma patients treated at the Ottawa Hospital in the preceding 5 years. Patients with central nervous system involvement were excluded. The questionnaires addressed cognitive function, pain, insomnia, fatigue, and mood. Of the patients in the sampling frame, 54 % responded to the survey and 42 % met inclusion/exclusion criteria. Sixteen percent (99/622) agreed to undergo computerized neuropsychological testing with CNS vital signs (CNSVS). Scores on the objective and subjective cognitive measures were compared to those of a healthy female control group from a previous study.

Results

The lymphoma group scored significantly lower than the controls on a cognitive rating scale (p = .018) and on CNSVS (p = .035). The difference on the CNSVS was primarily due to poorer attention and executive function scores in the lymphoma patients. The patients also had a higher frequency of impairment on both the objective (p = .009) and subjective (p < .001) cognitive measures. Among the lymphoma survivors, fatigue and anxiety were related to subjective cognitive disturbance (p < .001 for both), whereas pain was the only psychosocial measure associated with objective cognitive performance (p < .001).

Conclusions

These results suggest that cognitive disturbance may be a significant survivorship issue for lymphoma patients and should be more thoroughly investigated in this population.
Fußnoten
1
Scores on the FACT-Cog subscales are also reported in Table 3.
 
2
This served to eliminate age differences between the controls and lymphoma patients (see Table 1).
 
3
Square root transformations were applied to reaction time and working memory scores to correct for negative skewness in the data but, as this did not substantively alter the results, we report on the analyses with untransformed scores for ease of interpretation.
 
4
PIR, ISI, PHQ-9, and GAD-7 scores were all positively skewed; FACT-F was negatively skewed, both in the full lymphoma sample and the subgroup of patients who did the CNSVS. These variables were transformed to correct the distributions but this had no appreciable impact on the outcome of the analyses. For ease of interpretation, we report here on the results obtained using the raw scores.
 
Literatur
1.
Zurück zum Zitat Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an indepth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232CrossRefPubMedPubMedCentral Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an indepth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Moore HCF (2014) An overview of chemotherapy-related cognitive dysfunction or “chemobrain”. Oncology 28:797–804PubMed Moore HCF (2014) An overview of chemotherapy-related cognitive dysfunction or “chemobrain”. Oncology 28:797–804PubMed
5.
Zurück zum Zitat Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Pre-chemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324–331CrossRefPubMed Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Pre-chemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324–331CrossRefPubMed
6.
Zurück zum Zitat Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N (2015) Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst:107. doi:10.1093/jnci/djv099 Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N (2015) Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst:107. doi:10.​1093/​jnci/​djv099
7.
Zurück zum Zitat Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, Reneman L, Schagen SB (2015) Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment—the role of fatigue. Neuroimage Clin 7:547–554CrossRefPubMedPubMedCentral Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, Reneman L, Schagen SB (2015) Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment—the role of fatigue. Neuroimage Clin 7:547–554CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Schilder CM, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB (2010) The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology 19:415–422. doi:10.1002/pon.1595 CrossRefPubMed Schilder CM, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB (2010) The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology 19:415–422. doi:10.​1002/​pon.​1595 CrossRefPubMed
9.
Zurück zum Zitat Tannock IF, Ahles TA, Ganz PA, Van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239CrossRefPubMed Tannock IF, Ahles TA, Ganz PA, Van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239CrossRefPubMed
11.
Zurück zum Zitat Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM, Potosky AL (2013) Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119:672–680. doi:10.1002/cncr.27781 CrossRefPubMed Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM, Potosky AL (2013) Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119:672–680. doi:10.​1002/​cncr.​27781 CrossRefPubMed
12.
Zurück zum Zitat van der Poel MW, Oerlemans S, Schouten HC, Mols F, Pruijt JF, Maas H, van de Poll-Franse LV (2014) Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 93:811–819. doi:10.1007/s00277-013-1980-1 CrossRefPubMed van der Poel MW, Oerlemans S, Schouten HC, Mols F, Pruijt JF, Maas H, van de Poll-Franse LV (2014) Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 93:811–819. doi:10.​1007/​s00277-013-1980-1 CrossRefPubMed
13.
Zurück zum Zitat Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA (2013) Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81:84–92CrossRefPubMedPubMedCentral Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA (2013) Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81:84–92CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology 14:101–108CrossRefPubMed Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology 14:101–108CrossRefPubMed
15.
Zurück zum Zitat Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JEC, Abrey LE, Batchelor TT, Schiff D (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145–1151. doi:10.1093/annonc/mdl464 CrossRefPubMed Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JEC, Abrey LE, Batchelor TT, Schiff D (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145–1151. doi:10.​1093/​annonc/​mdl464 CrossRefPubMed
16.
Zurück zum Zitat Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA (2009) Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 24:689–698CrossRefPubMed Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA (2009) Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 24:689–698CrossRefPubMed
17.
Zurück zum Zitat Harder H, Van Gool AR, Duivenvoorden HJ, Cornelissen JJ, Eijkenboom WM, Barge RM, van den Bent MJ (2007) Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results. Eur J Cancer 43:2052–2059CrossRefPubMed Harder H, Van Gool AR, Duivenvoorden HJ, Cornelissen JJ, Eijkenboom WM, Barge RM, van den Bent MJ (2007) Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results. Eur J Cancer 43:2052–2059CrossRefPubMed
18.
Zurück zum Zitat Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heubner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A (2013) Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22:1509–1516. doi:10.1002/pon.3159 CrossRefPubMed Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heubner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A (2013) Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22:1509–1516. doi:10.​1002/​pon.​3159 CrossRefPubMed
19.
Zurück zum Zitat Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander AR, Koch U (2007) Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 39:789–799CrossRefPubMed Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander AR, Koch U (2007) Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 39:789–799CrossRefPubMed
20.
Zurück zum Zitat Syrjala KL, Dikmen S, Langer SL, Roth-Roemer S, Abrams JR (2004) Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood 104:3386–3392CrossRefPubMed Syrjala KL, Dikmen S, Langer SL, Roth-Roemer S, Abrams JR (2004) Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood 104:3386–3392CrossRefPubMed
21.
Zurück zum Zitat Devlen J, Maguire P, Phillips P, Crowther D, Chambers H (1987) Psychological problems associated with diagnosis and treatment of lymphomas. BMJ 295:953–957CrossRefPubMedPubMedCentral Devlen J, Maguire P, Phillips P, Crowther D, Chambers H (1987) Psychological problems associated with diagnosis and treatment of lymphomas. BMJ 295:953–957CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wesnes KA, Brooker H, Edgar C (2010) The disruptions to cognition, everyday function, and quality of life in oncology patients: a therapeutic opportunity? (abstract #11). Neurotherapeutics 7:331CrossRef Wesnes KA, Brooker H, Edgar C (2010) The disruptions to cognition, everyday function, and quality of life in oncology patients: a therapeutic opportunity? (abstract #11). Neurotherapeutics 7:331CrossRef
23.
Zurück zum Zitat Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMed Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMed
24.
Zurück zum Zitat Baudino B, D’Agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, Geda E, Castelli L, Mortara P, Orsi L, Cauda F, Sacco K, Ardito RB, Pinessi L, Geminiani G, Torta R, Bisi G (2012) The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. QJ Nucl Med Mol Imaging 56:1–10 Baudino B, D’Agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, Geda E, Castelli L, Mortara P, Orsi L, Cauda F, Sacco K, Ardito RB, Pinessi L, Geminiani G, Torta R, Bisi G (2012) The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. QJ Nucl Med Mol Imaging 56:1–10
25.
Zurück zum Zitat Zimmer P, Mierau A, Bloch W, Strüder HK, Hülsdünker T, Schenk A, Fiebig L, Baumann FT, Hahn M, Reinart N, Hallek M, Elter T (2015) Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma 56:347–352. doi:10.3109/10428194.2014.915546 CrossRefPubMed Zimmer P, Mierau A, Bloch W, Strüder HK, Hülsdünker T, Schenk A, Fiebig L, Baumann FT, Hahn M, Reinart N, Hallek M, Elter T (2015) Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma 56:347–352. doi:10.​3109/​10428194.​2014.​915546 CrossRefPubMed
26.
Zurück zum Zitat Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A (2013) Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22:1517–1527. doi:10.1002/pon.3163 CrossRefPubMed Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A (2013) Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22:1517–1527. doi:10.​1002/​pon.​3163 CrossRefPubMed
27.
Zurück zum Zitat Dillman D (2000) Mail and internet surveys: the tailored design method. Wiley, New York Dillman D (2000) Mail and internet surveys: the tailored design method. Wiley, New York
28.
Zurück zum Zitat Wagner LI, Lai JS, Cella D, Sweet J, Forrestal S (2004) Chemotherapy-related cognitive deficits: development of the FACT-Cog instrument. Ann Behav Med 27:S10 Wagner LI, Lai JS, Cella D, Sweet J, Forrestal S (2004) Chemotherapy-related cognitive deficits: development of the FACT-Cog instrument. Ann Behav Med 27:S10
29.
Zurück zum Zitat Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS et al (2014) Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol 67:811–820. doi:10.1016/j.jclinepi.2013.12.011 CrossRefPubMed Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS et al (2014) Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol 67:811–820. doi:10.​1016/​j.​jclinepi.​2013.​12.​011 CrossRefPubMed
32.
Zurück zum Zitat Jensen MP, Turner JA, Romano JM, Fisher LD (1999) Comparative reliability and validity of chronic pain intensity measures. Pain 83:157–162CrossRefPubMed Jensen MP, Turner JA, Romano JM, Fisher LD (1999) Comparative reliability and validity of chronic pain intensity measures. Pain 83:157–162CrossRefPubMed
33.
Zurück zum Zitat Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed
34.
Zurück zum Zitat Morin CM, Espie CA (2003) Insomnia: a clinical guide to assessment and treatment. Kluwer, New YorkCrossRef Morin CM, Espie CA (2003) Insomnia: a clinical guide to assessment and treatment. Kluwer, New YorkCrossRef
35.
Zurück zum Zitat Savard M, Savard J, Simard S, Ivers H (2005) Empirical validation of the insomnia severity index in cancer patients. Psychooncology 14:429–441CrossRefPubMed Savard M, Savard J, Simard S, Ivers H (2005) Empirical validation of the insomnia severity index in cancer patients. Psychooncology 14:429–441CrossRefPubMed
36.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–590PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–590PubMed
37.
Zurück zum Zitat Spitzer RL, Kroenke K, Williams JBW (1999) Validation and utility of a self-report version of prime-MD: the PHQ primary care study. JAMA 282:1737–1744CrossRefPubMed Spitzer RL, Kroenke K, Williams JBW (1999) Validation and utility of a self-report version of prime-MD: the PHQ primary care study. JAMA 282:1737–1744CrossRefPubMed
38.
Zurück zum Zitat Brown LF, Kroenke K, Theobald DE, Wu J, Tu W (2010) The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. Psychooncology 19:734–741CrossRefPubMedPubMedCentral Brown LF, Kroenke K, Theobald DE, Wu J, Tu W (2010) The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. Psychooncology 19:734–741CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Spitzer RL, Kroenke K, Williams JBW, Lowe B (2006) A brief measure for assessing generalized anxiety disorder. Arch Intern Med 166:1092–1097CrossRefPubMed Spitzer RL, Kroenke K, Williams JBW, Lowe B (2006) A brief measure for assessing generalized anxiety disorder. Arch Intern Med 166:1092–1097CrossRefPubMed
40.
Zurück zum Zitat Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, Elboim C, Abrams G, Merriman JD, Langford DJ, Leutwyler H, Baggott C, Kober K, Aouizerat BE, Miaskowski C (2015) Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. Biol Res Nurs 17:237–247CrossRefPubMed Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, Elboim C, Abrams G, Merriman JD, Langford DJ, Leutwyler H, Baggott C, Kober K, Aouizerat BE, Miaskowski C (2015) Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. Biol Res Nurs 17:237–247CrossRefPubMed
42.
Zurück zum Zitat Meyers CA, Albitar M, Estey E (2005) Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788–793CrossRefPubMed Meyers CA, Albitar M, Estey E (2005) Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788–793CrossRefPubMed
43.
Zurück zum Zitat Thornton LM, Andersen BL, Blakely WP (2010) The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation and the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol 29:333–337. doi:10.1037/a0018836 CrossRefPubMedPubMedCentral Thornton LM, Andersen BL, Blakely WP (2010) The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation and the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol 29:333–337. doi:10.​1037/​a0018836 CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934CrossRefPubMed Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934CrossRefPubMed
Metadaten
Titel
Cognitive function and its relationship to other psychosocial factors in lymphoma survivors
verfasst von
Dorothy Krolak
Barbara Collins
Lorelle Weiss
Cheryl Harris
Richard Van der Jagt
Publikationsdatum
11.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3480-z

Weitere Artikel der Ausgabe 3/2017

Supportive Care in Cancer 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.